U.S. Markets closed

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.73-0.37 (-0.95%)
At close: 4:00PM EST

38.73 0.00 (0.00%)
After hours: 4:00PM EST

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
http://www.revmed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees117

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark A. Goldsmith M.D., Ph.D.CEO, Pres & Chairman506.3kN/A1962
Ms. Margaret A. HornCOO & Gen. Counsel386.38kN/A1963
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.Pres of R&D426.35kN/A1961
Dr. Martin D. BurkeCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Michael A. FischbachAcademic Co-Founder & Member of Scientific Advisory BoardN/AN/A1981
Dr. Kevan M. ShokatAcademic Co-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Jack AndersVP of Fin. & Principal Accounting OfficerN/AN/A1977
Mr. David L. PomplianoFounding Chief Scientific OfficerN/AN/AN/A
Mr. Walter Reiher Ph.D.Chief Information OfficerN/AN/AN/A
Ms. Luan M. WilfongSr. VP of HRN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.

Corporate Governance

Revolution Medicines, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.